INTRODUCTION {#S1}
============

The application of stem cell technology to the field of sensory biology promises unparalleled experimental access to the cells and molecules underlying human touch and pain. Further development in this area may enable novel drug screening approaches for chronic pain and facilitate more relevant modeling of disease. However, human peripheral sensory neurons are particularly challenging to recreate *in vitro* because they are an inherently heterogenous cell population. *In vivo*, their cell bodies reside in peripheral ganglia, which contain a rich array of functionally disparate neuron subtypes. Sensory neurons establish synapses in the spinal cord and send long processes to peripheral targets, such as the skin ([@R57]). There, they form specialized nerve endings that transduce environmental stimuli into electrical signals that are relayed back to the spinal cord and brain.

Peripheral sensory neurons can be functionally grouped into at least three broad categories ([@R46]): (1) low-threshold mechanoreceptors (LTMRs) are responsible for the mechanotransduction of innocuous forces, including vibration, discriminative touch, and gentle brushing; (2) proprioceptors are a distinct class of mechanosensory neuron specialized to convey information about joint angle and body position; and (3) nociceptors and thermoreceptors are tuned to sense painful or thermal stimuli, including damaging mechanical force, noxious chemicals, heat, and cold. Nociceptor and thermoreceptor neurons can be further broken down into discrete subtypes with overlapping and often polymodal functional properties.

Although the basic signaling pathways in sensory neuron development are known, the transcriptional and environmental factors underpinning the extraordinary subtype diversity of these neurons remain mysterious ([@R46]). Furthermore, whether it is possible to derive a pure population of an individual sensory subtype *in vitro* is a major unresolved question. Methods exist to produce human sensory neurons from pluripotent stem cells ([@R3]; [@R18]; [@R41]; [@R66]; [@R67]). However, these protocols require complex and varied media formulations to accurately direct stem cell differentiation by chemical means, and they can yield heterogeneous or ill-defined sensory neuron populations.

Recently, forced expression of specific neural transcription factors has been shown to directly reprogram mouse and human fibroblasts to resemble peripheral sensory neurons ([@R11]; [@R78]). The resulting induced sensory neurons (iSNs) are functional but also heterogeneous, and they represent a minority of the total cells in culture. However, similar approaches that instead use induced pluripotent stem cells (iPSCs) as a starting population have shown remarkably high induction rates of cortical or motor neuron types depending on the transcription factors used ([@R54]; [@R84]; [@R85]). Neuronal differentiation performance can be further maximized by engineering iPSC lines with genomically integrated constructs harboring doxycycline-inducible transcription factors ([@R54]; [@R79]; [@R32]).

Here, we applied a genome engineering strategy to establish a human iPSC-based sensory neuron differentiation method, utilizing the transcription factors *NGN2* and *BRN3A*. Stably integrating an inducible construct into the genome of iPSCs allowed for the controlled co-expression of *NGN2* and *BRN3A*. A previous study has demonstrated that these two transcription factors, when simultaneously delivered via separate lentiviral vectors, can reprogram a fraction of fibroblasts into a mixed culture of sensory neuron subtypes ([@R11]). By contrast, we found that our approach selectively converts iPSCs into a homogeneous culture of a single sensory neuron subtype, able to transduce both cold and mechanical stimuli. Although this neuronal subtype has not been observed in mice ([@R60]; [@R70]), we validated the existence of similar neurons in adult human tissue. By combining the forced expression of *NGN2* and *BRN3A* with a traditional neural crest differentiation protocol, we were able to produce two additional sensory neuron subtypes, including a pure population of LTMRs. Lastly, we applied these methods to investigate the molecular basis of a rare neurogenetic human disorder, caused by loss-of-function mutations in the mechanosensitive ion channel *PIEZO2*. Patients with this condition present clinically with a profoundly impaired sensation of vibration, gentle touch, and proprioception. These data establish transcriptional programming of iPSCs as a means to derive functionally homogeneous sensory neurons *in vitro*, which reflect human-specific cell types and enable human disease modeling.

RESULTS {#S2}
=======

*NGN2-BRN3A* Programming in iPSCs Induces a Peripheral Sensory Neuron Phenotype {#S3}
-------------------------------------------------------------------------------

Fibroblasts can be converted into peripheral sensory neurons at approximately 5%--10% efficiency by forced overexpression of the transcription factors *NGN2* and *BRN3A* ([@R11]). With the goal of designing a simple yet effective sensory neuron induction system, we created an expression cassette containing the coding sequences of *NGN2* and *BRN3A* (*NGN2-BRN3A*) separated by a T2A ribosomal-skipping peptide and under the control of a doxycycline-inducible promoter ([Figure S1A](#SD1){ref-type="supplementary-material"}). This strategy enables equimolar and regulated expression of both factors in tandem ([@R22]; [@R49]). The vector also contained homology arms against the *CLYBL* genomic safe-harbor site. We chose *CLYBL* because of its greater capacity for stable transgene expression, as compared with other loci such as *AAVS1* ([@R17]). Using a characterized pair of transcription activator-like effector nucleases (TALENs) targeting the *CLYBL* locus ([@R17]), we genetically engineered a control human iPSC line (WTC11) ([@R56]) to stably harbor the *NGN2-BRN3A* construct by homology-directed repair. The construct included a constitutively expressed EGFP reporter and puromycin resistance, flanked by loxP sites. These allowed for visual identification and drug selection of stably integrated, single-cell-derived iPSC colonies. This was followed by Cre recombinase treatment to excise the reporter and selection genes ([Figure S1B](#SD1){ref-type="supplementary-material"}). Targeted insertion of the *NGN2-BRN3A* construct was verified by PCR genotyping ([Figure S1C](#SD1){ref-type="supplementary-material"}). With the aim of achieving robust transgene expression, we used only clones with insertion at both *CLYBL* alleles for further experiments. To test the expression activity of the transgene, we supplemented doxycycline to the culture medium and assayed *NGN2-BRN3A* expression by RT-PCR ([Figure S1D](#SD1){ref-type="supplementary-material"}). At baseline, transgene expression was undetectable. However, the addition of doxycycline stimulated *NGN2-BRN3A* transcription within 48 h, which was reversible upon withdrawal of the drug.

*NGN2-BRN3A*-engineered iPSCs exhibited normal growth characteristics in the absence of doxycycline, having roughly a 24-h doubling time ([Video S1](#SD2){ref-type="supplementary-material"}). We next assessed cellular morphology over time with continuous presence of doxycycline in a neural growth medium. To avoid biasing lineage decisions, the medium was devoid of small-molecule inhibitors traditionally used for neural differentiation (see [STAR Methods](#S11){ref-type="sec"}). Approximately 48 h after doxycycline application, we noticed a rapid loss of pluripotent morphology as the cells physically separated from one another and synchronously ceased dividing ([Figure 1A](#F1){ref-type="fig"}; [Video S2](#SD3){ref-type="supplementary-material"}). Over the next 5 days, the cells extended an elaborate network of processes. By day 14, the culture reached a stable, uniform neuronal appearance with large, rounded soma morphologies. We observed reduced differentiation efficiency and increased cell death when doxycycline was withdrawn before this time point (data not shown), so all described experiments include doxycycline for the first 14 days of differentiation.

We compared these cultures with neurons induced with *NGN2* expression alone, which produces a glutamatergic cortical layer 2/3 neuron population ([Figure 1A](#F1){ref-type="fig"}; [@R85]; [@R79]). Compared with *NGN2-BRN3A*-induced neurons, *NGN2*-induced neurons showed subtle differences in differentiation speed and morphology, extending bipolar processes by day 4 and ultimately adopting a more angular soma consistent with a pyramidal neuron identity. Both *NGN2-BRN3A* and *NGN2* neurons maintained their morphology upon withdrawal of doxycycline on day 14. By day 21, *NGN2-BRN3A*-induced cultures tended to form dense bundles of processes reminiscent of fasciculated axon tracts, which was not observed in *NGN2*-induced cultures ([Figure 1B](#F1){ref-type="fig"}). Immunocytochemical analysis of both culture types revealed distinct expression patterns of the dendritic marker MAP2 and the intermediate neurofilament peripherin (PRPH), a protein abundantly found in the peripheral nervous system ([@R33]). Peripherin was selectively expressed in *NGN2-BRN3A* cultures, whereas MAP2 showed greater distribution in *NGN2* cultures, consistent with the elaborate dendritic arbor of central nervous system neurons ([Figure 1B](#F1){ref-type="fig"}). Because *NGN2-BRN3A* neurons exhibited a mature neuronal morphology at this time point, further experiments were performed no earlier than 21 days after doxycycline induction (and 7 days after its withdrawal).

Peripheral axons can be defined by their diameter, in order from large to small: Aα, Aβ, Aδ, and C, with C fibers being unmyelinated. In mice, Nefh (NF200) is a heavy neurofilament specific to the myelinated fiber types Aα, Aβ, and Aδ. However, a recent analysis of NEFH in human dorsal root ganglia (DRG) demonstrated nearly universal fiber expression ([@R65]). By contrast, peripherin is most highly expressed in unmyelinated C fibers and some Aδ fibers in both mice and humans ([@R33]; [@R36]; [@R76]). Thus, similar to human sensory ganglia C or Aδ fibers, we found extensive co-localization of NEFH and peripherin in *NGN2-BRN3A* neurons ([Figure 1C](#F1){ref-type="fig"}). To further investigate the peripheral identity of *NGN2-BRN3A* neurons, we used antibodies against a neuronal nuclear marker (NeuN) and the transcription factors *BRN3A* and *ISL1* ([Figure 1C](#F1){ref-type="fig"}), which are expressed in all sensory neurons *in vivo* ([@R28]). Most of the culture population was labeled by these antibodies, indicating a near-complete conversion ([Figure 1D](#F1){ref-type="fig"}).

Endogenous sensory neurons have a distinct repertoire of neurotrophin receptors based on their functional identity ([@R53]). In mice, nociceptor (pain) and thermoreceptor (temperature) neurons express the receptor TrkA, encoded by *Ntrk1* ([@R30]). Subtypes of LTMR (gentle touch) neurons express TrkB (*Ntrk2*) ([@R48]), TrkC (*Ntrk3*) ([@R5]), or some combination ([@R60]). Proprioceptor (body position) neurons express only TrkC ([@R58]). Labeling *NGN2-BRN3A* neurons with antibodies against these receptor proteins revealed abundant and homogeneous expression of TRKB, but minimal to no expression of TRKC and TRKA ([Figure 1C](#F1){ref-type="fig"}), reminiscent of an Aδ LTMR subtype previously described in mice ([@R48]).

The above experiments indicate that forced co-expression of *NGN2* and *BRN3A* for 14 days in human iPSCs efficiently generates cells that resemble a subset of peripheral sensory neurons. As with other neural lineage conversions, *NGN2-BRN3A* induction rapidly yields a neuronal morphology, likely bypassing some or all of the natural embryonic progenitor stages ([@R84]; [@R85]). For this reason, we will refer to the converted cells as iSNs.

iSNs Express a Subset of Sensory Neuron Genes {#S4}
---------------------------------------------

To better define the iSN gene expression profile, and to determine to what degree they correspond to *in vivo* sensory neurons, we conducted RNA sequencing on bulk iSN cultures at day 21. Based on the expression of TRKB (*NTRK2*), we hypothesized that iSNs could represent a variety of LTMRs, which are a category of skin-innervating neurons responsible for transducing innocuous mechanical stimuli. In agreement with earlier immunocytochemistry results, *NTRK2*, but not *NTRK1* or *NTRK3*, was highly upregulated in iSNs relative to undifferentiated iPSCs ([Figure 2A](#F2){ref-type="fig"}). In addition to the other markers assessed by antibody labeling, we observed a subset of neuronal genes enriched to a similar degree between iSNs and human donor DRG. Among genes involved in neurotransmitter synthesis, iSNs expressed the vesicular glutamate transporter *SLC17A7* (VGLUT1), suggesting an excitatory glutamatergic neuron identity. A variety of neurotransmitter receptor genes were also detected, including those for acetylcholine and GABA, and to a lesser extent, *N*-methyl-D-aspartate (NMDA), AMPA, and kainate-type glutamate receptor subunits.

Due to the current lack of detailed knowledge regarding human sensory neuron gene expression patterns, it is difficult to assign a specific endogenous subtype identity to an *in-vitro*-derived cell population. Relying primarily on information from the mouse literature, we examined gene transcripts that might infer the presence of different sensory neuron categories in iSN cultures. The voltage-gated sodium channel Na~V~1.7, encoded by *SCN9A*, is ubiquitous in peripheral sensory neuron subtypes and is critical for the transmission of sensory stimuli in humans ([@R26]). *SCN9A* was robustly expressed in iSNs, but not the nociceptor-specific *SCNA10A* (Na~V~1.8) and *SCN11A* (Na~V~1.9) ([Figure 2A](#F2){ref-type="fig"}). Supporting a non-nociceptive identity, iSNs were devoid of most genes involved in pain, itch, and temperature sensation. Three notable exceptions were the inflammatory peptide substance P (*TAC1*), the purinergic receptor *P2RX3*, and the cold receptor *TRPM8* ([Figure 2A](#F2){ref-type="fig"}).

Murine *Trpm8* is always co-expressed with TrkA and peripherin, representing a specific class of small- and medium-diameter fibers ([@R25]; [@R44]; [@R72]). In iSNs, the expression of *TRPM8* but the absence of TRKA precluded direct assignment to any known sensory neuron subtype ([Figure 2A](#F2){ref-type="fig"}). We also found expression of *PIEZO2*, the mechanotransduction ion channel underlying proprioception and gentle touch sensation ([@R62]; [@R83]). However, iSNs showed virtually no expression of *MAF* or *RUNX3*, which mark *PIEZO2*-expressing Aβ LTMRs and proprioceptive neurons, respectively ([@R47]; [@R82]). iSNs also had detectable levels of *NGN2* (*NEUROG2*), which is not found in the adult human DRG ([Figure 2A](#F2){ref-type="fig"}). This could be an effect of residual doxycycline-induced *NGN2-BRN3A*. It can take up to 72 h for the transgenic RNA transcript to dissipate after doxycycline removal ([Figure S1D](#SD1){ref-type="supplementary-material"}), and transgenic *NGN2* is known to recruit expression of endogenous *NGN2* ([@R85]). These unexpected gene expression patterns indicate that iSNs may represent an immature, artifactual, or otherwise unknown cell population that mimics certain features of native sensory neurons.

iSNs and Human DRG Neurons Co-express *TRPM8* and *PIEZO2* {#S5}
----------------------------------------------------------

*Trpm8* and *Piezo2* are mutually exclusive in mouse sensory ganglia, highlighting a labeled line for cold sensation that is separate from mechanosensation ([@R43]; [@R60]; [@R70]). Because our bulk iSN RNA sequencing dataset showed expression of both *TRPM8* and *PIEZO2*, we reasoned iSN cultures might be a mixture of neurons with non-overlapping expression of these two genes. We carried out RNA *in situ* hybridization on iSNs to determine the population distribution of *TRPM8* and *PIEZO2*, as well as lineage-defining neurotrophin receptor transcripts. Corroborating the previous immunocytochemistry and RNA sequencing experiments, *NTRK1* was absent, whereas *NTRK2* was prevalent, in essentially every cell ([Figure 2B](#F2){ref-type="fig"}). *NTRK3* was also detectable across the entire population at a much lower level. Co-expression of the corresponding proteins TRKB and TRKC has been described in a subset of mouse DRG neurons ([@R31]). Surprisingly, the majority of iSNs also co-expressed *TRPM8* and *PIEZO2*, based on a conservative measurement of ≥ 5 labeled mRNA puncta of each transcript per cell ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). With these criteria, we conclude that iSNs are a relatively homogeneous population that unexpectedly co-expresses *TRPM8* and *PIEZO2* in conjunction with *NTRK2* and low levels of *NTRK3*.

In the adult human DRG, *PIEZO2* is abundantly expressed ([@R65]), but its relationship to *TRPM8* is unknown. We performed dual-label RNA *in situ* hybridization on DRG tissue from four unrelated human donors to assess the expression pattern of both genes ([Table S1](#SD1){ref-type="supplementary-material"}). DAPI was used, which most strongly labels non-neuronal satellite cell nuclei, in combination with the pan-neuronal gene *TUBB3* to identify individual neuron somas by *TUBB3*^+^ circular recesses in the tissue ([Figure S2A](#SD1){ref-type="supplementary-material"}).

Among neurons labeled by *PIEZO2* and *TRPM8* probes, the majority expressed only *PIEZO2*, whereas a small fraction was exclusively marked by *TRPM8* ([Figure 2D](#F2){ref-type="fig"}). Intriguingly, a large subset of neurons expressed both *PIEZO2* and *TRPM8*, as seen in the iSNs, and outnumbered those expressing only *TRPM8* ([Figures 2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}, and [S2B](#SD1){ref-type="supplementary-material"}). Furthermore, we found that some DRG neurons seem to express *TRPM8* with *NTRK2*, also like the iSNs, but the lower quality of our *NTRK2* labeling prevented rigorous quantification ([Figure S2C](#SD1){ref-type="supplementary-material"}). These findings suggest that the co-expression of TRPM8, PIEZO2, and NTRK2 might define a molecular class of sensory neuron found in humans, but not mice.

iSNs Detect Cold and Mechanical Stimuli {#S6}
---------------------------------------

A sensory neuron that expresses *TRPM8* and *PIEZO2* should be equipped to transduce both cold and mechanical stimuli. We used the calcium dye Fluo-4 to monitor iSN calcium activity in real time at different temperatures. Shifting the recording medium from 25°C to 4°C induced a robust and sustained calcium influx across the entire culture ([Figures 3A](#F3){ref-type="fig"}--[3C](#F3){ref-type="fig"}). The *TRPM8* inhibitor RQ-00203078 reversibly blunted the calcium response. By contrast, application of 50°C heat had no effect on iSN activity ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}).

Menthol is a chemical chilling agent from mint plants that is a natural ligand of TRPM8 ([@R55]; [@R61]). Application of this compound elicited a calcium response similar to cold temperature ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}; [Video S3](#SD4){ref-type="supplementary-material"}). We also evaluated other pungent chemicals targeting different TRP channels. Allyl isothiocyanate (AITC) from mustard plants is a ligand of TRPA1 ([@R7]; [@R42]), and capsaicin from chili peppers is a ligand of the heat-sensing channel TRPV1 ([@R16]). Consistent with the absence of these ion channels in the RNA sequencing data, iSNs showed essentially no response to AITC and capsaicin ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Some neurons exhibited minor calcium transients in the presence of AITC, which can be attributed to its additional role as a weak TRPM8 agonist ([Figure 3C](#F3){ref-type="fig"}; [@R40]). Based on the expression of the purinergic receptor *P2RX3* in iSNs, we tested the P2RX3 ligand α,β-methylene-ATP, a molecule that induces chronic pain in mice ([@R21]; [@R39]). Application of α,β-methylene-ATP did not produce a sustained calcium influx, but the basal rate of iSN spontaneous activity drastically increased ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). This type of response is likely due to the fast inactivation of the P2RX3 channel ([@R21]).

Next, we used whole-cell patch clamp to assess iSN electrophysiological properties. In current clamp, resting potential was generally between −55 and −65 mV, and action potential trains were elicited by current injection ([Figure 3D](#F3){ref-type="fig"}). Bath application of tetrodotoxin completely blocked action potential generation. This is consistent with absence of the tetrodotoxin-resistant sodium channels Na~V~1.8 and Na~V~1.9, which are exclusive to nociceptors ([@R26]).

Resting potential was held at −60 mV in voltage clamp and the cell membrane was indented by a blunt probe to interrogate the mechanosensitivity of iSNs ([Figure 3E](#F3){ref-type="fig"}; [Video S4](#SD5){ref-type="supplementary-material"}). We observed an inward current with rapid inactivation kinetics that increased in amplitude with greater indentation ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}). Mechanically activated, rapidly adapting currents are found in a variety of sensory neurons that mediate touch detection ([@R38]). Genetic deletion of *PIEZO2* in mice and in human iPSC-derived LTMRs ablates these currents ([@R62]; [@R66]). Given that the iSNs here manifest a similar current and express *PIEZO2*, this ion channel is likely the molecular transducer underlying iSN mechanosensitivity.

Varied Induction of NGN2-BRN3A Expression in Neural Crest Yields Divergent Sensory Neuron Populations {#S7}
-----------------------------------------------------------------------------------------------------

The most common sensory neuron differentiation methods use small-molecule inhibitors in a stepwise protocol to guide iPSCs through the natural stages of embryonic development, first reaching a neural crest progenitor stage before terminal differentiation ([@R3]; [@R18]; [@R41]; [@R67]). However, the forced expression of lineage-specific transcription factors has recently been applied to directly induce fibroblasts into sensory neurons ([@R11]; [@R78]). We wondered whether such transcriptional programming of iPSCs using a generic sensory neuron code, in the absence of natural developmental patterning signals, might be responsible for the unusual gene expression profile of our iSNs.

To test the above hypothesis, we adapted an established method to first differentiate iPSCs into neural crest cells ([@R6]), which are the multipotent stem cells that naturally give rise to peripheral sensory neurons *in vivo*. Only a small fraction of neural crest cells spontaneously differentiates toward a sensory neuron fate *in vitro* (data not shown) ([@R66]). Therefore, we evaluated the combined effect of our iSN conversion protocol with neural crest development. Similar to iPSCs, exposure of neural crest to doxycycline for 14 days caused a rapid and uniform differentiation to a neuronal morphology ([Figure 4A](#F4){ref-type="fig"}). We will refer to these cells as neural crest-derived iSN population 1 (NC-iSN1).

During sensory development in mice, the neurogenic factor NGN2 is transiently upregulated in neural crest cells that ultimately become LTMR and proprioceptor neurons ([@R52]). In a recent study, iPSC-derived neural crest was specifically directed toward an LTMR fate with \~20% efficiency by the brief overexpression of *NGN2* and early exposure to neurotrophic factors and retinoic acid ([@R66]). We took an analogous approach here, treating the cells with doxycycline for only 24 h to transiently induce NGN2-*BRN3A* expression ([Figure 4A](#F4){ref-type="fig"}). In conjunction with the sensory neuron transcriptional program, sensory neuron subtype development and survival is influenced by exposure to retinoic acid and several neurotrophic factors: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3) ([@R2]; [@R12]; [@R15]; [@R51]; [@R63]). To approximate the *in vivo* signaling milieu, we supplemented retinoic acid and all four neurotrophic factors at the same time as doxycycline, and we maintained their presence for the course of the experiment ([Figure 4A](#F4){ref-type="fig"}). Strikingly, under these conditions, the neural crest differentiated into a homogeneous neuronal population with massive cell bodies. We will refer to these cells as neural crest-derived iSN population 2 (NC-iSN2).

Measuring the soma area of each cell population revealed the significantly larger size of NC-iSN2 relative to NC-iSN1 and the original iPSC-derived iSNs ([Figure 4B](#F4){ref-type="fig"}). Both NC-iSN1s and NC-iSN2s were labeled by antibodies for peripherin, NEFH, and ISL1, suggesting a peripheral sensory identity ([Figure 4C](#F4){ref-type="fig"}). Based on their large diameter, we considered that NC-iSN2s might have acquired an LTMR phenotype as reported previously ([@R66]). LTMRs are specialized touch receptor neurons that lack the TRP ion channels for temperature and chemical detection. RNA *in situ* hybridization showed complete absence of *TRPM8* but a uniform expression of *PIEZO2* ([Figure 4C](#F4){ref-type="fig"}). Consistent with an LTMR identity, NC-iSN2s exhibited rapidly adapting inward currents in response to mechanical stimulation ([Figure 4D](#F4){ref-type="fig"}). In contrast, NC-iSN1s recapitulated the co-expression of both *TRPM8* and *PIEZO2* originally seen in iPSC-derived iSNs ([Figure 4C](#F4){ref-type="fig"}). Thus, simply altering the timing of developmental signals and the duration of *NGN2-BRN3A* induction can switch the neural crest fate decision between two distinct sensory neuron populations.

Transcriptomic Analysis of iSN Subtypes Derived from iPSCs and Neural Crest {#S8}
---------------------------------------------------------------------------

Recent single-cell analyses of mouse DRG have enabled molecular classification of different sensory neuron subtypes ([@R20]; [@R60]; [@R75]). Because our three iSN populations appear to be mostly homogeneous cultures, each of a single or a few related cell types, we applied bulk RNA sequencing to identify transcriptomic differences between iSNs, NC-iSN1s, and NC-iSN2s. We partitioned selections of genes based on existing mouse sensory neuron categories ([Figure 4E](#F4){ref-type="fig"}; [@R75]). iSNs and NC-iSN1s were markedly similar, with expression of LTMR genes but lacking the LTMR-specific transcription factors *MAF* and *MAFA*. They also expressed non-overlapping sets of genes found in peptidergic nociceptors (PEPs). iSN samples were enriched for the inflammatory peptide substance P (*TAC1*) as described earlier. NC-iSN1s instead expressed the beta form of calcitonin gene-related peptide, encoded by *CALCB* ([Figure 4E](#F4){ref-type="fig"}).

NC-iSN2s expressed LTMR genes similarly to iSNs and NC-iSN1s, but they additionally included *MAF* and *MAFA* and generally lacked expression in other subtype categories ([Figure 4E](#F4){ref-type="fig"}). NC-iSN2s also showed selective upregulation in a group of homeobox (HOX) genes ([Figure S3](#SD1){ref-type="supplementary-material"}). HOX genes are targeted by retinoic acid signaling and encode transcription factors that control rostral-caudal neural development ([@R9]). Supplementation of retinoic acid during motor neuron induction from embryonic stem cells shifts the positional identity from rostral to caudal via HOX gene activation, but it does not affect the overall motor neuron phenotype ([@R54]). We suspect the HOX gene expression in NC-iSN2s is similarly unrelated to their LTMR phenotype, but rather is an independent effect of retinoic acid supplementation.

It is unclear whether the peripherin expression in NC-iSN2s is an artifact of *NGN2-BRN3A* programming or is a natural feature of some human LTMRs ([Figures 4C](#F4){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}). In mice, anti-peripherin antibodies most strongly label medium- and small-diameter sensory neurons, with minimal labeling of large-diameter LTMRs and proprioceptors ([@R33]). However, *in situ* hybridization and single-cell sequencing reveal expression of peripherin mRNA in all mouse sensory neurons (Allen Mouse Spinal Cord Atlas) ([@R20]; [@R60]; [@R75]). These data indicate that peripherin is broadly expressed in sensory ganglia and, when measured in isolation, may not reliably mark specific neuron subtypes. Also, DRG explant cultures show a drastic increase in the number of peripherin-expressing fibers, which is associated with regenerating axons ([@R33]). Dissociation of DRG explants further alters gene expression patterns, inducing ectopic co-expression of TrkA, TrkB, and TrkC ([@R34]). Therefore, the atypical expression of certain genes in cultured neurons, including the iSN subtypes derived here, may be an artifact of a persistent regenerative *in vitro* state. In the only other study that we are aware of to generate human LTMR-like neurons, peripherin was not investigated ([@R66]).

The retina-specific peripherin (*PRPH2*) ([@R4]) and motor neuron homeodomain transcription factor (*MNX1*) ([@R74]) were absent in all three iSN culture populations, strengthening the conclusion that these iSN subtypes most closely recapitulate neurons of peripheral sensory ganglia ([Figure S3](#SD1){ref-type="supplementary-material"}). As previously noted with iPSC-derived iSNs, NC-iSN1s also expressed endogenous *NGN2* (*NEUROG2*), but NC-iSN2s did not. This persistent *NGN2* expression may be brought on by the prolonged doxycycline treatment in iSNs and NC-iSN1s. It remains to be seen whether longer-term culture after doxycycline withdrawal would extinguish the *NGN2* expression. These observations suggest that extended activation of the *NGN2-BRN3A* transgene overrides an LTMR transcriptional program, yielding an unexpected *TRPM8*^+^/*PIEZO2*^+^ cell type.

Some neural induction methods, including *NGN2* and *BRN3A* programming of sensory neurons directly from fibroblasts ([@R11]), yield a population of mixed neuronal subtypes ([@R78]; [@R84]). To definitively establish the inter- and intra-population heterogeneity of different iSNs, we performed single-nuclei RNA sequencing on NC-iSN1s and NC-iSN2s. Individual cells from the two iSN populations were analyzed and algorithmically clustered based on transcriptional similarity ([Figure 5A](#F5){ref-type="fig"}; see [STAR Methods](#S11){ref-type="sec"}). NC-iSN1s and NC-iSN2s formed separate groups with little crossover, except for some NC-iSN2s that clustered among NC-iSN1s. Both conditions showed remarkable homogeneity within themselves, and no meaningful sub-clusters were identified based on differential expression of sensory genes. Inspecting single genes revealed agreement between the bulk and single-nuclei RNA sequencing. Both cell clusters expressed *SCN9A* and *PIEZO2*, only NC-iSN1s expressed *TRPM8*, and *TRPV1* was essentially absent ([Figure 5B](#F5){ref-type="fig"}). Thus, the two neural crest-derived populations are each comprised of a distinct and homogeneous iSN subtype.

Absence of Mechanically Activated Current in iSNs from Patients with Touch and Proprioception Deficiency {#S9}
--------------------------------------------------------------------------------------------------------

One application of iPSC technology is exploring the impact of genetic variation on human physiology. We recently reported a rare sensory disorder in two unrelated individuals caused by loss-of-function mutations in *PIEZO2* (PIEZO2^LOF^) ([@R19]). This condition is clinically characterized in part by a profound congenital lack of proprioception, vibratory sense, and gentle touch detection on glabrous skin. To investigate sensory neuron function in this disorder, we reprogrammed iPSCs from the two PIEZO2^LOF^ patients and one unaffected sibling; the latter harbors a single apparently recessive loss-of-function allele ([Table 1](#T1){ref-type="table"}).

We integrated the *NGN2-BRN3A* transgene cassette, as described earlier, into the CLYBL safe-harbor locus in these iPSC lines. The iPSCs were then validated with quality-control measures alongside the healthy control line WTC11 ([Figure S4](#SD1){ref-type="supplementary-material"}). Next, we established that they could efficiently differentiate into BRN3A^+^/ISL1^+^ iSNs ([Figures S5A](#SD1){ref-type="supplementary-material"} and [S5B](#SD1){ref-type="supplementary-material"}). All iSNs expressed TRKB and, to a lesser extent, TRKC, but not TRKA ([Figures S6A](#SD1){ref-type="supplementary-material"} and [S6B](#SD1){ref-type="supplementary-material"}). We also confirmed the presence of *PIEZO2* by *in situ* hybridization. PIEZO2^LOF^ iSNs had a noticeably diminished amount of *PIEZO2* transcript ([Figure S6B](#SD1){ref-type="supplementary-material"}). This is speculatively due to nonsense-mediated mRNA decay, consistent with previous evaluation of PIEZO2^LOF^ patient skin biopsies ([@R19]). Overall, iSN morphology and gene expression profile were similar across all cell lines ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}), demonstrating *NGN2-BRN3A* programming as an efficient and robust tool to derive sensory-like neurons from diverse genetic backgrounds.

To generate an isogenic control line, we used CRISPR-Cas9 to correct the putative PIEZO2^LOF^ variants in iPSCs from the second patient ([Figure S7A](#SD1){ref-type="supplementary-material"}). Corrected wild-type *PIEZO2* sequences and normal karyotype were confirmed in isolated clones ([Figures S7B](#SD1){ref-type="supplementary-material"} and [S7C](#SD1){ref-type="supplementary-material"}). Following conversion to iSNs, *in situ* hybridization on corrected cells indicated robust *PIEZO2* expression ([Figure S7D](#SD1){ref-type="supplementary-material"}). We used short tandem repeat (STR) analysis to verify that the identity of corrected iPSCs matched the unedited patient iPSCs. In the two clones tested, both showed identical STR lengths at all alleles except for the STR locus on chromosome 18, which was homozygous in the corrected clones but heterozygous in the uncorrected patient line ([Table S2](#SD1){ref-type="supplementary-material"}). In a third corrected clone, we found an abnormal karyotype due to monosomy 18 (data not shown). *PIEZO2* is located on the short arm of chromosome 18, whereas the chromosome 18 STR is located on the long arm. Based on the available evidence, we conclude that in the corrected clones with normal karyotype, one chromosome was likely corrected and subsequently duplicated, replacing the other chromosome 18. The missing copy of chromosome 18 may have become unstable because of CRISPR-Cas9-induced double-strand breaks if homology-directed repair did not occur ([@R50]). Because we were unable to isolate a biallelic corrected clone retaining each original copy of chromosome 18, we used the existing karyotypically normal clones with isodisomy 18 in the remaining experiments with this caveat in mind.

As an additional control, we generated a PIEZO2 knockout line on the genetic background of the WTC11 healthy control. Designing two CRISPR-Cas9 guide RNAs flanking *PIEZO2* exon 1 allowed for complete excision of this region on both alleles, including the start codon ([Figures S7E](#SD1){ref-type="supplementary-material"}--[S7G](#SD1){ref-type="supplementary-material"}). Producing iSNs from these knockout iPSCs, we validated the absence of *PIEZO2* mRNA transcript by *in situ* hybridization ([Figure S7H](#SD1){ref-type="supplementary-material"}).

It has been previously shown that genetic deletion of *PIEZO2* in human iPSC-derived LTMRs ablates their mechanically activated current ([@R66]). If the genetic variants in PIEZO2^LOF^ patients are truly loss-of-function, we would expect the PIEZO2-dependent sensory neurons of these subjects to be similarly defective in sensing mechanical force. To test this hypothesis, we produced iSNs from all six control and patient cell lines ([Table 1](#T1){ref-type="table"}). We then mechanically stimulated neuron somas while recording whole-cell currents ([Figure 6C](#F6){ref-type="fig"}). Both healthy control and unaffected sibling control iSNs reliably responded with rapid- or intermediate-adapting currents, respectively. It is unclear why recorded currents from the unaffected sibling (C2) were more challenging to stimulate to saturation and exhibited a slower adaptation rate, but the PIEZO channel family is known to display different inactivation times depending on alternative splicing or other cellular contexts ([@R24]; [@R64]; [@R70]). Variance in mechanically evoked current adaptation may also be an artifact of variability inherent to the *in vitro* differentiation system or genetic background of different cell lines. In contrast, iSNs from the two PIEZO2^LOF^ patients, as well as the *PIEZO2* knockout, were insensitive to mechanical stimuli. Genetically corrected patient iSNs showed a complete rescue of rapidly adapting mechanically activated current ([Figure 6D](#F6){ref-type="fig"}). Importantly, iSNs from all cell lines responded to menthol regardless of their mechanical sensitivity ([Figure 6E](#F6){ref-type="fig"}). Our findings establish that iSNs from PIEZO2^LOF^ patients are unable to transduce mechanical force, yet they retain the gene expression profile and menthol sensitivity that are characteristic of this *in vitro* cell type.

DISCUSSION {#S10}
==========

Human sensory biology has remained largely enigmatic because of the inaccessibility of functional human nerve tissue. iPSC technology presents an opportunity to capture species- and individual-specific qualities of development, physiology, and disease *in vitro*. In this study, we used transcription factor programming to efficiently generate three separate, distinct, and homogeneous populations of peripheral sensory neurons from human iPSCs. We then applied this system to evaluate the impact of *PIEZO2* genetic variants on sensory mechanotransduction.

Existing sensory neuron differentiation techniques produce cells with heterogenous response properties ([@R11]; [@R18]; [@R78]). By overexpressing *NGN2* and *BRN3A*, a previous study by [@R11] showed direct lineage conversion of mouse and human fibroblasts into iSNs at roughly 5%--10% efficiency. This method produces a mixed culture of morphologically and functionally diverse iSNs with differential responses to AITC, capsaicin, and menthol. Our approach instead harnesses the intrinsic differentiation capacity of iPSCs to produce near-pure iSN cultures. These iSNs express a specific collection of sensory genes, depending on their method of derivation, and are homogeneous in morphology and function. It will be interesting to see whether systematic application of different transcription factor combinations and developmental signals can recreate the many clinically relevant sensory neuron subtypes *in vitro*.

Several methodological variables could be responsible for the homogeneity of our iSNs and for the heterogeneity of the iSNs produced by [@R11]. Whereas [@R11] used fibroblasts as a starting population, we used iPSCs. This difference in starting cell populations is particularly relevant because epigenetic states are known to influence the outcome of lineage reprogramming ([@R80]). Also, [@R11] delivered the *NGN2* and *BRN3A* transcription factors on separate lentiviral vectors. We used a single genome-integrated construct expressing the two factors from the same promoter, separated by a T2A ribosomal-skipping peptide, resulting in equimolar expression of these factors. We speculate that the outcome of transcriptional programming experiments may be sensitive to the relative dosing of individual transcription factors. Methods utilizing a single factor, or factors expressed in a 1:1 ratio, often yield homogeneous cultures like the iSNs in our study ([@R54]; [@R77]; [@R85]). Conversely, independent transmission of multiple factors, which each cell may express differently, can result in heterogenous differentiation ([@R10]; [@R84]). This principle was recently demonstrated by [@R10], revealing the interplay between two transcription factors as the determinant of an embryonic lineage decision. Future work will have to delineate the impact of transgene delivery methods on the stochasticity of cellular reprogramming.

An unexpected feature of the iSNs produced in this study is the co-expression of *TRPM8* and *PIEZO2*. It is still unclear to what degree TRPM8^+^/PIEZO2^+^ iSNs mimic an *in vivo* human sensory neuron subtype. Our observation that certain human DRG neurons co-express *TRPM8* and *PIEZO2* indicates that this category of cell may exist *in vivo*, despite its absence in mice ([@R60]; [@R70]). Following the partial similarity of iSNs to LTMRs and their lack of nociceptor markers, we would expect *in vivo TRPM8*^+^/*PIEZO2*^+^ neurons to be polymodal non-nociceptive Aβ or Aδ fibers, specialized to transduce cold and mechanical stimuli. This neuron subtype could provide a molecular explanation for long-observed physiological and psychological phenomena. "Weber's deception" is the perception that cold objects feel heavier than warmer objects ([@R81]). This illusion is proposed to be mediated by mechanosensory neurons that also transduce cold ([@R14]). Classic single-fiber recordings in cat, monkey, and human sensory nerves have reported "cold-mechanoreceptors" that fit this description ([@R1]; [@R35]; [@R37]; [@R45]; [@R69]; [@R73]). Given the paucity of data on human sensory ganglia ([@R23]; [@R65]; [@R86]), further investigation will be critical to determine the presence of specific hitherto unrecognized cellular subtypes in humans and their similarity between commonly used animal models.

We were also surprised to observe that, in iPSC-derived neural crest, the duration of transcription factor expression influences differentiation between two sensory neuron fates. Long-term *NGN2-BRN3A* induction generates a TRPM8^+^/PIEZO2^+^ neuron subtype (NC-iSN1) similar to the original iSNs, whereas short-term *NGN2-BRN3A* induction leads to neurons resembling canonical LTMRs (NC-iSN2). We suggest that long-term expression of *NGN2-BRN3A* sets a transcriptional cascade of events distinct from short-term *NGN2-BRN3A* expression, ultimately activating different gene-regulatory networks. This is based on the observation that transcription factors relocate over time through synergistic interactions with other proteins ([@R77]). This iSN model system may serve as a platform to further explore how epigenetic status and transcription factor timing shape cell fate decisions.

Here, we additionally showed that PIEZO2^LOF^ patient iSNs are completely insensitive to mechanical stimulation, but they otherwise retain all other characteristics of iSNs, including menthol responsiveness. These *in vitro* data are consistent with clinical evaluation of PIEZO2^LOF^ patients demonstrating intact thermal sensation ([@R19]). This provides proof-of-principle that iSNs faithfully recapitulate aspects of human physiology, as reflected in the strikingly selective sensory phenotype of congenital PIEZO2 deficiency. Further, it adds direct evidence to the existing literature that PIEZO2 is the mechanotransduction channel underlying gentle touch and proprioception in humans.

The efficient derivation of homogeneous iSNs described in this study will facilitate disease studies and drug screens that rely on bulk or high-throughput approaches. Our simple induction protocol, leveraging engineered human iPSC technology, is well suited to this purpose, obviating many culture re-plating steps and the need for complex media with small-molecule inhibitors. The iSNs reported here natively express several genes with clinical relevance for migraine and chronic pain, including *TRPM8* ([@R27]), *PIEZO2* ([@R29]; [@R59]; [@R71]), *TAC1* (substance P) ([@R68]), *P2RX3* ([@R21]; [@R39]; [@R68]), and *SCN9A* (Na~V~1.7) ([@R26]). These findings set the basis for improved *in vitro* platforms where target genes can be efficiently interrogated in a sensory neuron context.

STAR ★ METHODS {#S11}
==============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Six human iPSC lines were generated and/or engineered for sensory neuron differentiation in this study, as detailed in [Table 1](#T1){ref-type="table"}. These cell lines, and the NGN2-BRN3A plasmid used for the genome engineering, are available from the Lead Contact with a Material Transfer Agreement. Information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Carsten Bönnemann (<carsten.bonnemann@nih.gov>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### NGN2-BRN3A construct design and genomic insertion {#S14}

Codon optimized human *BRN3A* was synthesized (Epoch Life Science) and subcloned into a Tet-ON 3G pUCM vector already containing a T2A-linked human *NGN2* and CLYBL homology arms, derived from the publicly available pUCM-CLYBL-hNIL plasmid (Addgene, \#105841). iPSCs were transfected with Lipofectamine Stem according to manufacturer's instructions (STEM00003, Thermo Fisher) to deliver a left and right CLYBL TALEN pair (Addgene, \#62196 and \#62197) ([@R17]) with the *NGN2-BRN3A* donor construct. Clones were selected with puromycin and genotyped with three different PCR primer pairs (IDT). See [Key Resources Table](#T2){ref-type="table"} for a list of PCR primers used. Refer to [@R32] for a detailed protocol on the iPSC genome engineering strategy.

### iPSC reprogramming {#S15}

The WTC11 control iPSC line was derived and characterized previously ([@R56]). Written informed consent for patient skin biopsies was obtained by a qualified investigator (protocol 12-N-0095 approved by the National Institute of Neurological Disorders and Stroke, National Institutes of Health). Dermal fibroblasts from skin biopsies of PIEZO2^LOF^ patients and an unaffected sibling ([@R19]) were reprogrammed to iPSCs with the CytoTune-iPS 2.0 Sendai kit (Thermo Fisher, A16517) following a standard protocol described elsewhere ([@R8]). All iPSC clones were verified free of mycoplasma contamination and checked for normal karyotype after 10 passages. Karyotyping and STR analyses were performed by WiCell (Madison, WI, USA). See [Key Resources Table](#T2){ref-type="table"} for a list of primers (IDT) used for Sanger sequencing (GeneWiz) on PIEZO2^LOF^ patient genomic DNA.

### CRISPR-Cas9 editing of PIEZO2 in iPSCs {#S16}

To generate the PIEZO2 knockout line, WTC11 iPSCs were dissociated in TrypLE Express, and 600,000 cells were plated per well of a 6-well plate coated with Matrigel (Corning, 354277) in 2.5 mL E8 medium with 1x RevitaCell supplement. After 30 minutes, transfection was accomplished using 4 μL Lipofectamine Stem Reagent in 200 μL OptiMEM with 20 pmol of each modified sgRNA (Synthego) to target upstream and downstream of PIEZO2 exon 1 (5^′^-ACCCAGAGCCCGGTGGGCGA-3^′^ and 5^′^- TGAGTCTG GTCCGCTTTCCG-3^′^) and 1,800 ng eSpCas9-GFP mRNA. On the second day after transfection, GFP positive iPSCs were sorted onto Matrigel-coated 96-well plates containing 100 μL E8 Flex with 1x CloneR supplement (STEMCELL Technologies 05889) at one cell per well. Wells with surviving clones after 10 days were expanded to isolate gDNA for screening. A genomic fragment spanning the gRNA target sites was amplified using primers 5^′^- GCATCAGCTACCCCTGAAGA --3^′^ and 5^′^- CCAGAGCCCTTCACTTTGTT--3^′^ with Phusion Hot Start Flex DNA Polymerase (NEB M0535) and GC buffer and Sanger sequenced (Eurofins Genomics) to identify PIEZO2 exon 1 deletion clones. All products were from Thermo Fisher unless otherwise mentioned.

The corrected PIEZO2^LOF^ patient line was generated by the Genome Engineering and iPSC Center at Washington University School of Medicine (St. Louis, MO). Lines were created using a sgRNA cloned into an expression vector (gift from Keith Joung, Addgene plasmid 43945) co-nucleofected with Cas9 plasmid p3a-Cas9HC (gift from Jin-Soo Kim, Addgene 43945) and a single-stranded oligonucleotide donor (IDT). sgRNA sequence was 5^′^-GCTGACCAGAGAAATTAAGA-3^′^. Oligonucleotide donor sequence was (from 5^′^ to 3^′^):

ACTTGGCTTAACTCCATTTCAAGGGAGCATATTGATATATCTACAGTTCTGAGAATTGAACGATGCATGCTGACCCGGGAAATTA AGAAGGTAACACTGCTGGTGTAATTCTTTTTGCTCCTTCCCACATTAAGAAGACATTAAAAGTCA.

### iPSC culture {#S17}

iPSCs were maintained on tissue culture-treated polystyrene plates with Matrigel (Corning, 354277) in E8 medium (Thermo Fisher, A1517001). The medium was changed daily and the iPSCs were split every 4 -- 6 days using Accutase (Invitrogen, A1110501). The rho kinase (ROCK) inhibitor 10 μM Y-27632 (Tocris, 1254) was included in the medium on the day of passaging.

### Induced sensory neuron differentiation {#S18}

iSNs were differentiated similarly to cortical induced neurons ([@R79]). On day 0, iPSCs were dissociated with Accutase, and 20,000 cells/cm^2^ were plated on Matrigel-coated dishes in neural differentiation medium (NDM) supplemented with 10 mM Y-27632 and 2μg/mL doxycycline (Clontech, 631311). NDM (all from Invitrogen) consisted of equal parts DMEM/F12 (11330032) and Neurobasal medium (21103049), containing GlutaMAX (35050061), B27 (17504044), and N2 (17502048). The medium could be optionally changed on day 1 to remove Y-27632, but is otherwise the same composition. On day 2, the cells were dissociated with Accutase, and 50,000 cells/cm^2^ were seeded on plates coated with 0.1% polyethylenimine (Sigma-Aldrich, P3143) and 15 μg/mL laminin (Invitrogen, 23017015) in NDM with doxycycline. The medium was changed every other day through day 8, after which only half volume medium changes were made. If undifferentiated cells persist, 20 μM BrdU (Sigma-Aldrich, B9285--50MG) could be optionally added on day 4 to eliminate dividing cells and achieve a pure neuronal culture. Starting on day 8 onward, neurotrophic factors (NTFs) (all R&D Systems) were added to the NDM, consisting of BDNF (248BD025), GDNF (212GD010), β-NGF (256GF100), and NT-3 (267N3025), each at 10 ng/mL. Doxycycline was discontinued starting on day 14.

For NC-iSN1 and NC-iSN2 generation, the neural crest differentiation was a modified form of previous protocols ([@R6]; [@R66]). On day --1 iPSCs were dissociated with Accutase and seeded in an Aggrewell 400 plate for spheroid formation (STEMCELL Technologies, 34411) according to manufacturer's instructions in E8 medium with 10 μM Y-27632. On day 0, spheroids were transferred to uncoated tissue culture-treated dishes in NDM with 20 μg/mL bFGF (R&D Systems, 233FB025), 20 μg/mL EGF (R&D Systems, 236EG200), and 10 μM of the TGF-β receptor ALK4/5/7 inhibitor SB431542 (Tocris, 1614). This medium was changed every other day. SB431542 was discontinued starting on day 6. After 1--2 weeks, spheroids spontaneously attached to the culture surface and neural crest cells migrated outward. All spheroids were manually removed, and the neural crest cells were re-plated at 40,000 cells/cm^2^ on polyethylenimine and laminin-coated dishes in NDM -- this is denoted as day 0 of neural induction. For NC-iSN1s, doxycycline was added from day 0 until day 14, and NTFs were supplemented beginning on day 8. For NC-iSN2s, doxycycline was added on day 0 for 24 hours. NTFs and 50 nM retinoic acid (Sigma-Aldrich, R2625) were supplemented from day 0 onward. On day 2, the neural crest cells were re-plated for the final time onto polyethylenimine and laminin-coated dishes at 50,000 cells/cm^2^. Medium was changed every other day, and half medium changes were made after day 8.

METHOD DETAILS {#S19}
--------------

### Immunocytochemistry {#S20}

Cells were washed in PBS, followed by fixation in 4% PFA for 10 minutes, and washed again in PBS prior to antibody labeling. Cells were first permeabilized with 0.25% Triton X-100 for 5 minutes and then blocked with 10% serum for up to 2 hours. Primary antibody labeling was performed overnight at 4°C in 3% serum. Primary antibody was washed and replaced with secondary antibody in 3% serum at room temperature for 60 minutes. The cells were then washed and counterstained with DAPI before mounting on slides. Images were acquired on a Nikon Eclipse Ti-E inverted microscope or on a Leica TSC SP5 II confocal microscope.

### RNA *in situ* hybridization {#S21}

Cells were washed with PBS, fixed for 30 minutes with 4% PFA, washed in PBS again, and serially dehydrated by increasing ethanol gradients up to 100% and stored at −20°C. *In situ* hybridization was performed with an RNAscope kit (ACD, 320851) following manufacturer's instructions. Probes were used (all ACD) against *NTRK1* (402631), *NTRK2* (402621-C2), *NTRK3* (406341-C3), *TRPM8* (543121), *TRPM8* (543121-C3), *PIEZO2* (449951), *PIEZO2* (449951-C2), and *TUBB3* (318901-C2). Images were acquired on a Leica TSC SP5 II confocal microscope with 63x objective.

For human DRG staining, we obtained tissue from three different healthy donors ([Table S1](#SD1){ref-type="supplementary-material"}) through the NIH NeuroBioBank, University of Maryland, Baltimore, MD and the Tissue for Research bank ([https://biobankonline.com](https://biobankonline.com/)). Tissue from a fourth donor was purchased from AnaBios Inc., San Diego, CA ([Table S1](#SD1){ref-type="supplementary-material"}). The tissue was fresh frozen, cryosectioned, then labeled using the RNAscope kit (ACD) by manufacturer's instructions. To quench tissue autofluorescence, sections were treated with TrueVIEW (Vector Labs) and TrueBlack (Biotium) following the manufacturer's instructions just before coverslip mounting. For quantification and the representative images in [Figures S2A](#SD1){ref-type="supplementary-material"}--[S2C](#SD1){ref-type="supplementary-material"}, DRG sections were imaged on a Nikon Eclipse Ti confocal microscope with a 40x objective. For [Figure 2D](#F2){ref-type="fig"}, the sections were imaged on a Zeiss LSM 880 confocal microscope with a 40x objective.

### RNA extraction and RT-PCR {#S22}

RNA was extracted from iSNs using TRIzol (Thermo Fisher, 15596018) and chloroform and purified with an miRNeasy kit (QIAGEN, 217004) following manufacturer's instructions. Total RNA was reverse transcribed with SuperScript III (Thermo Fisher, 18080085) and ancillary reagents according to the manufacturer. The resulting cDNA was diluted to 5 ng/μL and used for end-point or quantitative PCR (qPCR). qPCR was performed in triplicate wells per sample using the Taqman Gene Expression Assay (Thermo Fisher, 4369510) on a QuantStudio 6 Flex machine (Thermo Fisher). Mock reverse-transcribed RNA was used as a negative control. End-point PCR was accomplished using an Advantage 2 PCR kit (Takara) and visualized on agarose gels. See [Key Resources Table](#T2){ref-type="table"} for a list of RT-qPCR and end-point PCR primers used.

### Bulk RNA sequencing {#S23}

Total RNA quantity and integrity were assessed on a Bioanalyzer (Agilent). For the human DRG (Clontech 636150) and iPSCs, sequencing libraries were constructed from 100 ng -- 500 ng of total RNA using the TruSeq Stranded Total RNA kit (Illumina) with Ribo-Zero following the manufacturer's instructions. The fragment size of the libraries was verified using the Agilent 2100 Bioanalyzer (Agilent) and the concentrations were determined using Qubit instrument (Thermo Fisher). The libraries were loaded onto the Illumina HiSeq 3000 for 2 × 75 base pair paired-end read sequencing at approximately 40 million reads per sample. The fastq files were generated using the bcl2fastq software for further analysis. For the iSN samples, 500 ng total RNA was used in conjunction with the TruSeq Stranded Total RNA Library Prep kit (Illumina) to prepare libraries. The library quality was checked via Bioanalyzer and quantitated by Qubit (Thermo Fisher). Equimolar quantities from each library were pooled and run on a NextSeq 500/550 High Output kit v2.5 (150 cycles) (Illumina, 20024907) at approximately 40 million paired-end reads per sample.

### Single-nuclei RNA sequencing {#S24}

iSNs were washed in ice-cold PBS and lysed in ice-cold Nuclei EZ lysis buffer (Sigma-Aldrich, NUC-101). Samples were then filtered by a 40 μm strainer (Thermo Fisher), and centrifuged in 4°C at 800 g for 8 minutes. The pelleted nuclei were resuspended in 1% BSA in PBS, and a trypan blue-stained aliquot was counted using a hemocytometer. Nuclei were again pelleted and resuspended at a volume appropriate for the 10X Chromium system (10X Genomics). The nuclei were counted a second time to verify the quantity and to inspect the nuclei quality. 10X Chromium processing and library production were done following manufacturer's instructions. V2 chemistry and Next Gen sequencing were performed on an Illumina NextSeq 500 machine.

### Calcium imaging {#S25}

All calcium imaging was performed in Ringer's solution: 125 mM NaCl, 3 mM KCl, 5 mM CaCl~2~, 1 mM MgCl~2~, 10 mM glucose, and 10 mM HEPES (all from Sigma-Aldrich), adjusted to pH 7.3 with 1 M NaOH, and osmolality measured \~280 mmol/kg. First, cells differentiated for at least 21 days were rinsed in Ringer's solution and incubated for 1 hour at room temperature in Fluo-4 AM (Thermo Fisher, F14201) with Pluronic F-127 (Thermo Fisher, P-3000MP) in Ringer's solution following manufacturer's instructions. The cells were then rinsed in Ringer's solution and imaged in Ringer's solution at room temperature on an Olympus IX73 inverted microscope using a pco.panda sCMOS back-illuminated camera at 2 frames per second. The AMPA receptor antagonist NBQX (Tocris, 0373) was included in the imaging solution at 10 mM to prevent false positive signals from neural network activity.

All imaging trials began with 30 s of baseline measurement before the cells were exposed to chemicals or temperature-specific solutions by micropipette. The chemicals used were AITC (377430), capsaicin (M2028), menthol (M2772), α,β-meATP (M6517), and RQ-00203078 (SML1602) (all from Sigma-Aldrich). Concentrations of each chemical are noted in their respective figure legends, and temperature-specific solutions were verified by mercury thermometer prior to use.

### Electrophysiology {#S26}

Whole-cell currents were recorded by a Multiclamp 700B amplifier (Molecular Devices). A Digidata 1550 digitizer (Molecular Devices) was used to digitize recorded signals at 100 kHz, followed by low pass filtering at 10 kHz, and recordings were saved through Clampex 10.3 software (Molecular Devices). The bath solution was made with 133 mM NaCl, 3 mM KCl, 2.5 mM CaCl~2~, 1 mM MgCl~2~, 10 mM glucose, and 10 mM HEPES, adjusted to 7.3 pH with NaOH, and had an osmolality of \~280 mmol/kg. Patch pipettes were pulled and polished to a resistance of 4 -- 8 MU. For current-clamp, the intracellular solution was made with 131 mM K-gluconate, 7 mM KCl, 1 mM CaCl~2~, 1 mM MgCl~2~, 1 mM BAPTA, 10 mM HEPES, 4 mM Mg-ATP, and 0.5 mM Na~2~-GTP, adjusted to 7.3 pH with KOH, and had an osmolality of \~280 mmol/kg. Tetrodotoxin (Tocris, 1078) was bath applied at a final concentration of 500 nM. For voltage-clamp, the intracellular solution was made with 133 mM CsCl, 1 mM CaCl~2~, 1 mM MgCl~2~, 5 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, and 0.5 mM Na~2~-GTP, adjusted to 7.3 pH with CsOH, and had an osmolality of \~275 mmol/kg. All reagents were from Sigma-Aldrich unless specifically mentioned.

Mechanical stimulation was accomplished with a blunt heat-polished pipette of 3 -- 5 μm tip diameter. A P841.20 piezoelectric translator mounted on a micromanipulator (Physik Instrumente) was used to drive the pipette at a 60° angle to the culture dish. The pipette was positioned at the surface of the cell and driven in a 1 -- 10 μm indentation series at 1 μm increment every 2 s, with 200 ms of indentation and a 2 ms ramp time. Only cells with less than 200 pA leak current that reached at least 6 μm of indentation before breakage of the whole-cell patch seal were kept for analysis.

### Video recording of cell cultures {#S27}

Time-lapse microscopy of NGN2-BRN3A engineered iPSCs ([Videos S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}) was performed with an IncuCyte S3 Live-Cell Analysis System. An image was acquired every 10 minutes over 72 hours then processed and exported using IncuCyte software. The mechanical stimulation assay ([Video S4](#SD5){ref-type="supplementary-material"}) was recorded on an Olympus IX73 inverted microscope using a pco.panda sCMOS back-illuminated camera with a 10 ms exposure time, and the frames were processed and exported using Fiji software.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S28}
---------------------------------------

### Confocal microscopy analysis {#S29}

Microscopy images were whole-image adjusted for brightness and contrast and quantified through Fiji software and plugins. For quantifying antibody and RNA *in situ* hybridization staining of iSNs, at least n = 3 coverslips per condition were tile-imaged, and the number of labeled cells in each fluorescent channel were counted by an observer blinded to cell line genotype. The criteria for positive RNA *in situ* hybridization staining was ≥ 5 fluorescent puncta per transcript per cell. For the analysis of human DRG dual probe RNA *in situ* hybridization experiments, whole sections of DRG were tile-imaged, and nonspecific autofluorescent background signal was removed by subtracting the fluorescence channel of probe 1 from probe 2 and vice versa. One whole section from each of n = 4 donors was quantified for *TRPM8* and *PIEZO2* probe labeling, with a cut-off of ≥ 10 fluorescent puncta per transcript constituting a positive cell.

### RT-qPCR analysis {#S30}

Transcript levels are expressed as cycle threshold (Ct) values as obtained from the QuantStudio 6 Flex machine software. Ct values were averaged across triplicate wells, normalized to the 60S ribosomal protein gene *RPLP0*, and multiplied by −1 for graphing purposes. Heatmaps were generated in GraphPad Prism 8.0.

### Bulk RNA sequencing analysis {#S31}

Fastq paired-end sequence files were first quality inspected with the FastQC tool, then adaptor clipped (TruSeq3-PE-2.fa:2:30:10) and trimmed to remove nucleotide bias (HEADCROP:11) and low quality calls (TRAILING:20 SLIDINGWINDOW:4:20 MINLEN:15) using the Trimmomatic tool (<http://www.usadellab.org/cms/?page=trimmomatic>). Then, the remaining intact read pairs per sample were imported into the CLCbio Genomics Workbench ([https://www.qiagenbioinformatics.com](https://www.qiagenbioinformatics.com/)) and down-sampled to 42 million reads each for the iSN samples. The iPSC and DRG samples did not require down-sampling. The reads were then reference mapped by sample to the human genome (GRCh38.82) in stranded fashion using the "RNA-Seq Analysis" tool supported under default parameters (v11). Expression for each known, annotated gene (Homo_sapiens.GRCh38.82.chr.gtf) in every sample was exported from the tool in TPM units and imported to R software for analysis ([http://cran.r-project.org](http://cran.r-project.org/)). In R, TPM expression was pedestalled by a value of 2 then Log~2~ transformed. Transformed expression values across samples were then quantile normalized. To ensure quality of the normalized expression, and absence of sample-level outliers, exploratory inspection was performed via Tukey boxplot, covariance-based PCA scatterplot, and correlation-based heatmap. To remove noise-biased expression values, locally weighted scatterplot smoothing (LOWESS) was applied across expression for all genes separately for each sample class (Coefficient of Variation mean expression). LOWESS fits were then over-plotted and inspected to identify the common low-end expression value where the relationship between mean expression (i.e., "signal") and Coefficient of Variation (i.e., "noise) grossly deviated from linearity (expression value = 3 for iSNs; expression value = 3.25 for iPSCs and DRG). These values were used to generate heat maps in GraphPad Prism 8.0 that were color-scaled such that genes below the noise threshold are on a blue gradient, and genes above are on a red gradient, with white representing the noise cutoff point of 3 or 3.25 TPM.

### Single-nuclei RNA sequencing analysis {#S32}

Sequencing data from the Illumina NextSeq 500 machine were aligned to human GRCh38.v25.premRNA-2.1.0 with CellRanger. Seurat V3.0 was used to analyze the data using standard methods described elsewhere ([@R13]).

### Calcium imaging analysis {#S33}

Analysis of calcium imaging videos was performed using Fiji software to draw regions of interest around randomly selected soma during the baseline period. Mean pixel intensities were measured across the entire time-lapse, and the peak intensity was extracted for each cell following each stimulus. Each value was normalized on a cell-by-cell basis by subtracting average baseline from peak intensity (Δ*F*) and dividing by the average baseline to achieve Δ*F/F*~*0*~. For individual cell scatterplots, the Δ*F/F*~*0*~ of each cell was further normalized to a percentage of the cell's peak KCl response.

### Electrophysiology analysis {#S34}

Clampfit 10.3 software (Molecular Devices) was used to visualize and quantify electrophysiological recordings. Recordings were baseline-adjusted and digitally filtered at 2 kHz before measuring peak currents from the mechanical stimulus. Individual traces and graphs were exported to GraphPad Prism 8.0 for graphing.

### Statistical analysis {#S35}

All statistical tests and graphs were done in GraphPad Prism 8.0 software. Data were first measured for normality by Shapiro-Wilk test. Depending on the data distribution, appropriate parametric or non-parametric one-way ANOVA methods with correction for multiple comparisons were used to determine significance. A P value of \< 0.05 was used as the cut-off criteria for statistical significance when comparing two or more sets of values. The degree of statistical significance, in asterisks, is reported in each figure legend along with the number of replicates, *n*, used in the test. All values are expressed as means ± SEM.

### Figure generation {#S36}

All graphs were generated using GraphPad Prism 8.0 software. Figures were created in Adobe Illustrator 2019. The graphical abstract was created with [BioRender.com](http://BioRender.com).

DATA AND CODE AVAILABILITY {#S37}
--------------------------

The bulk RNA sequencing data (GEO: GSE139273) and single-nuclei RNA sequencing data (GEO: GSE139409) from this study are publicly available at <https://www.ncbi.nlm.nih.gov/geo/> using the respective accession numbers listed.
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![*NGN2-BRN3A* Programming of Human iPSCs Efficiently Yields Induced Sensory Neurons\
(A) Protocol for sensory neuron induction using *NGN2-BRN3A*-engineered iPSCs. Phase-contrast images were captured on days 2, 4, 8, and 14 after doxycycline addition. Neurons induced with *NGN2* alone are shown on the bottom for comparison.\
(B) Phase-contrast and immunocytochemistry images of day 21 neurons induced by *NGN2-BRN3A* and *NGN2* only.\
(C) Immunocytochemistry of day 21 *NGN2-BRN3A* neurons to detect proteins found in sensory neurons.\
(D) Quantification of percent staining NeuN (78.9% ± 2.6%), BRN3A/NeuN (82.0% ± 1.7%), and ISL1/NeuN (90.1% ± 1.0%). For NeuN stains, n = 6 independent coverslips were used and were split for co-staining into n = 3 coverslips for BRN3A and n = 3 for ISL1. At least 200 cells were counted per stain. Values are expressed as mean ± SEM. Scale bars, 100 μm.\
Δ, medium change; 1/2Δ, half medium change; NTF, neurotrophic factor; Y-27632, ROCK inhibitor. See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Videos S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}.](nihms-1551549-f0001){#F1}

![iSNs and Human DRG Neurons Co-express *TRPM8* and *PIEZO2*\
(A) Heatmap of RNA sequencing results on iPSCs, iSNs, and adult human donor DRG (hDRG). Each column represents an individual sample's normalized log~2~ transcripts per million (TPM). The hDRG is a pooled RNA sample from 21 individuals.\
(B) RNA *in situ* hybridization on iSNs for transcripts of neurotrophin and sensory receptors. Each small fluorescent punctum roughly indicates one transcript. *TUBB3* encodes a general neuron class of microtubule, βIII-tubulin. Scale bars, 10 μm.\
(C) Quantification of *in situ* hybridization in iSNs using a cutoff criteria of ≥ 5 puncta per transcript for positive cells. *TRPM8*^+^ (17.9% ± 1.5%), *PIEZO2*^+^ (14.0% ± 4.6%), *TRPM8*^+^/*PIEZO2*^+^ (56.0% ± 6.3%), and *TUBB3*^+^ only (11.5% ± 3.4%). 199 cells were counted across n = 5 coverslips.\
(D) RNA *in situ* hybridization for *TRPM8* and *PIEZO2* in human DRG (hDRG). Labeled neurons are shown in wide-field view (left) with dotted, dashed, and solid circles indicating *TRPM8*^+^, *PIEZO2*^+^, and *TRPM8*^+^/*PIEZO2*^+^ neurons, respectively. Zoomed images of single neurons (right), individually marked by numbers in the wide-field view. Scale bars, 25 μm.\
(E) Quantification of human DRG *in situ* hybridization. *TRPM8*^+^ (12.8% ± 4.4%), *PIEZO2*^+^ (59.7% ± 6.8%), and *TRPM8*^+^/*PIEZO2*^+^ (27.4% ± 6.9%). 622 positive cells were counted across n = 4 DRG donors. All values are expressed as mean ± SEM.\
See also [Figure S2](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1551549-f0002){#F2}

![iSNs Detect Cold Temperature and Mechanical Force\
(A) Fluo-4 fluorescence images recording iSNs at 25°C and 4°C. The TRPM8 inhibitor RQ-00203078 was incubated at 10 μM for 5 min before resuming recording. A 5-min room temperature incubation was used in between each 4°C treatment. Scale bar, 500 μm.\
(B) Representative fluorescence traces of calcium imaging trials, with 5 cells shown per trial. Values are graphed as the change in fluorescence intensity from baseline and divided by the baseline (Δ*F/F*~*0*~). 100 μM AITC, 10 μM capsaicin, 500 μM menthol, and 50 μM α,β-methylene-ATP (α,β-meATP) were used.\
(C) Scatter dot plots of peak Δ*F/F*~*0*~ of individual cells after application of temperature or chemicals. Each cell is normalized to a percentage of its own KCl response at the end of the recording period. For each condition, ≥ 80 cells were analyzed. Post hoc comparisons of each treatment to vehicle with one-way ANOVA and Dunnett's correction for multiple comparisons. p values: 50°C, p = 0.99; 4°C pre, p = 0.0001; 4°C RQ, p = 0.5135; 4°C post, p = 0.001; AITC, p = 0.1379; capsaicin, p = 0.5242; menthol, p = 0.0001; α,β-meATP, p = 0.0001. \*\*\*\*p \< 0.0001.\
(D) Example whole-cell current-clamp recording of iSNs in response to depolarizing currents. A total of n = 4 cells were recorded without tetrodotoxin (TTX) andn = 5 cells with 1 μM TTX.\
(E) Mechanical stimulation of iSNs in whole-cell voltage-clamp mode. In the phase-contrast image, the recording pipette is on the left, and the stimulator probe is on the right. Scale bar, 20 μm. In the recording, the top trace indicates micrometer steps of the stimulator probe, whereas the bottom trace shows whole-cell currents.\
(F) Quantification of the current amplitude at each probe indentation depth. A total of n = 10 cells were recorded, with 10/10 cells displaying a peak mechanically evoked current above 50 pA. Values are expressed as mean ± SEM.\
See also [Videos S3](#SD4){ref-type="supplementary-material"} and [S4](#SD5){ref-type="supplementary-material"}.](nihms-1551549-f0003){#F3}

![Varied Induction of *NGN2-BRN3A* in Neural Crest Yields Divergent Sensory Neuron Populations\
(A) Protocol and phase-contrast images of neural crest differentiation with two strategies for sensory neuron induction (NC-iSN1 and NC-iSN2). Day 0 depicts neurectodermal spheroid formation in a microwell plate. Day 12 shows neural crest migration from an individual spheroid. Scale bars, 100 μm.\
(B) Quantification of cell soma area based on phase-contrast images across three differentiation experiments of iSNs (n = 301 cells), NC-iSN1s (n = 228 cells), and NC-iSN2s (n = 332 cells). Values are expressed as mean ± SEM. Post hoc comparisons with Kruskal-Wallis test and Dunn's correction for multiple comparisons, \*\*\*\*p \< 0.0001.\
(C) Representative immunohistochemistry and RNA *in situ* hybridization experiments on NC-iSN1s and NC-iSN2s. Scale bars, 25 μm.\
(D) Representative mechanical stimulation of NC-iSN2s in whole-cell voltage-clamp. A total of n = 6 cells were recorded.\
(E) RNA sequencing heatmap expression results of selected genes grouped by known sensory neuron subtype. Each heatmap column depicts the average log~2~ TPM of three independent samples.\
Δ, medium change; 1/2Δ, half medium change; C-LTMR, C fiber LTMR; LTMR, low-threshold mechanoreceptor; NC, neural crest; NP, nonpeptidergic nociceptor; PEP, peptidergic nociceptor; Proprio., proprioceptor. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1551549-f0004){#F4}

![Single-Cell RNA Sequencing of Neural Crest-Derived iSNs\
(A) Merged UMAP plot representing individual cells from a single differentiation of both NC-iSN1 (22,804 cells) and NC-iSN2 (15,004 cells).\
(B) Expression UMAP plots indicating cells in the upper 90% of the population distribution with mapped reads to specific genes, based on unique molecular identifier counts.](nihms-1551549-f0005){#F5}

![PIEZO2^LOF^ iSNs Are Insensitive to Mechanical Stimuli\
(A) Representative immunocytochemistry from at least three differentiations of control and patient iSNs. Scale bar, 50 μm.\
(B) qRT-PCR of sensory-related genes in day 21 iSNs, normalized to the housekeeping gene *RPLP0* and expressed as −ΔCt for color coding. Each column represents an independent sample, three samples per cell line. Human DRG (hDRG) total RNA was used as a positive control, and WTC11 iPSCs were used as a negative control. Text color denotes gene category: orange, pluripotency; magenta, pan-sensory; purple, LTMR; blue, proprioceptor; green, nociceptor and/or thermoreceptor.\
(C) Whole-cell voltage-clamp recordings of iSNs during mechanical stimulation. Traces are examples from n = 10 neurons for each cell line.\
(D) Quantification of mechanically activated current peak amplitudes in n = 10 cells per cell line. Values are expressed as mean ± SEM. Post hoc comparisons with Kruskal-Wallis test and Dunn's correction for multiple comparisons. \*p \< 0.05, \*\*p \< 0.01.\
(E) Scatter dot plot for peak Δ*F/F*~*0*~ of individual cells after exposure to 500 μM menthol, normalized to KCl response. For each cell line, ≥80 cells were analyzed. In post hoc comparisons between each sample with one-way ANOVA and Dunnett's correction for multiple comparisons, no comparison was significantly different (p \> 0.05).\
See also [Figures S4](#SD1){ref-type="supplementary-material"}--[S7](#SD1){ref-type="supplementary-material"} and [Table S2](#SD1){ref-type="supplementary-material"}.](nihms-1551549-f0006){#F6}

###### 

Summary of Human iPSC Lines

  Name    Donor Identity          Genotype                                                             Donor Age   Donor Gender   Donor Ancestry
  ------- ----------------------- -------------------------------------------------------------------- ----------- -------------- -------------------
  C1      healthy control 1       wild type                                                            30 years    male           Japanese
  C2      healthy sibling of P1   heterozygous recessive *PIEZO2* mutation c.4723C\>T                  21 years    female         Bangladeshi
  P1      PIEZO2 patient 1        compound heterozygous *PIEZO2* mutations c.4723C\>T and c.5053C\>T   19 years    female         Japanese/European
  P2      PIEZO2 patient 2        compound heterozygous *PIEZO2* mutations c.5054G\>C and c.5053C\>T   10 years    female         Bangladeshi
  P2^C^   PIEZO2 patient 2        CRISPR-Cas9-mediated *PIEZO2* correction in patient 2 iPSCs          see P2                     
  KO      healthy control 1       CRISPR-Cas9-mediated *PIEZO2* knockout in control 1 iPSCs            see C1                     

  REAGENT or RESOURCE                                                          SOURCE                                IDENTIFIER
  ---------------------------------------------------------------------------- ------------------------------------- -------------------------------
  Antibodies                                                                                                         
  Peripherin                                                                   Abcam                                 ab4666; RRID: AB_449340
  MAP2                                                                         Abcam                                 ab5392; RRID: AB_2138153
  NEFH                                                                         Abcam                                 ab72996; RRID: AB_2149618
  TUJ1 (mouse)                                                                 Abcam                                 ab78078; RRID: AB_2256751
  TUJ1 (chicken)                                                               Abcam                                 ab107216; RRID: AB_10899689
  NeuN                                                                         Abcam                                 ab104225; RRID: AB_10711153
  BRN3A                                                                        Millipore                             MAB1585; RRID: AB_94166
  ISL1                                                                         DSHB                                  40.2D6; RRID: AB_528315
  TRKA                                                                         Abcam                                 ab76291; RRID: AB_1524514
  TRKB                                                                         Alomone Labs                          ANT-019-AG; RRID: AB_10917156
  TRKC                                                                         OriGene                               TA336908
  OCT4                                                                         Abcam                                 ab19857; RRID: AB_445175
  SSEA4                                                                        STEMCELL Technologies                 60062
  NANOG                                                                        ReproCELL                             RCAB0004P-F; RRID: AB_567470
  TRA-1--81                                                                    Millipore                             MAB4381; RRID: AB_177638
  SOX2                                                                         Thermo Fisher                         PA1--16968; RRID: AB_2195781
  TRA-1--60                                                                    Millipore                             MAB4360; RRID: AB_2119183
  Chemicals, Peptides, and Recombinant Proteins                                                                      
  Y-27632                                                                      Tocris                                1254
  Doxycycline                                                                  Clontech                              631311
  BDNF                                                                         R&D Systems                           248BD025
  GDNF                                                                         R&D Systems                           212GD010
  β-NGF                                                                        R&D Systems                           256GF100
  NT-3                                                                         R&D Systems                           267N3025
  bFGF                                                                         R&D Systems                           233FB025
  EGF                                                                          R&D Systems                           236EG200
  SB431542                                                                     Tocris                                1614
  Retinoic acid                                                                Sigma-Aldrich                         R2625
  AITC                                                                         Sigma-Aldrich                         377430
  Capsaicin                                                                    Sigma-Aldrich                         M2028
  Menthol                                                                      Sigma-Aldrich                         M2772
  α,β-meATP                                                                    Sigma-Aldrich                         M6517
  RQ-00203078                                                                  Sigma-Aldrich                         SML1602
  Tetrodotoxin                                                                 Tocris                                1078
  Critical Commercial Assays                                                                                         
  Taqman Gene Expression Assay                                                 Thermo Fisher                         18080085
  Taqman RT-qPCR probes (see Oligonucleotides below)                           Thermo Fisher                         N/A
  RNAscope® Fluorescent Multiplex Detection Reagents                           ACD                                   320851
  RNAscope® Probe -- Hs-TRPM8                                                  ACD                                   543121
  RNAscope® Probe -- Hs-TRPM8-C3                                               ACD                                   543121-C3
  RNAscope® Probe -- Hs-PIEZO2                                                 ACD                                   449951
  RNAscope® Probe -- Hs-PIEZO2-C2                                              ACD                                   449951-C2
  RNAscope® Probe -- Hs-NTRK1                                                  ACD                                   402631
  RNAscope® Probe -- Hs-NTRK2-C2                                               ACD                                   402621-C2
  RNAscope® Probe -- Hs-NTRK3-C3                                               ACD                                   406341-C3
  RNAscope® Probe -- Hs-TUBB3-C2                                               ACD                                   318901-C2
  Deposited Data                                                                                                     
  Bulk RNA sequencing data                                                     <https://www.ncbi.nlm.nih.gov/geo/>   Accession GSE139273
  Single-nuclei RNA sequencing data                                            <https://www.ncbi.nlm.nih.gov/geo/>   Accession GSE139409
  Experimental Models: Cell Lines                                                                                    
  WTC11 iPSC                                                                   [@R56]                                Coriell GM25256
  WTC11 NGN2 iPSC                                                              [@R79]                                N/A
  WTC11 NGN2-BRN3A iPSC (C1)                                                   This study                            N/A
  WTC11 NGN2-BRN3A iPSC, PIEZO2 knockout (KO)                                  This study                            N/A
  PIEZO2 patient 1 NGN2-BRN3A iPSC (P1)                                        This study                            N/A
  PIEZO2 patient 1 healthy sibling NGN2-BRN3A iPSC (C2)                        This study                            N/A
  PIEZO2 patient 2 NGN2-BRN3A iPSC (P2)                                        This study                            N/A
  PIEZO2 patient 2 NGN2-BRN3A iPSC, CRISPR-Cas9-corrected (P2^C^)              This study                            N/A
  Oligonucleotides                                                                                                   
  CLYBL wild type genotyping primer, forward: 5′-TGACTAAACACTGT GCCCCA-3′      This study                            N/A
  CLYBL wild type genotyping primer, reverse: 5′-AGGCAGGATGAAT TGGTGGA-3′      This study                            N/A
  CLYBL 5′ insert genotyping primer, forward: 5′-CAGACAAGTCAGT AGGGCCA-3′      This study                            N/A
  CLYBL 5′ insert genotyping primer, reverse: 5′-AGAAGACTTCCTCT GCCCTC-3′      This study                            N/A
  CLYBL 3′ insert genotyping primer, forward: 5′-GGTAGGAAGTGGT ACGGAAA-3′      This study                            N/A
  CLYBL 3′ insert genotyping primer, reverse: 5′-GAACGATTTACTGG GCAGTC-3′      This study                            N/A
  *NGN2-BRN3A* transgene RT-PCR primer, forward: 5′-CAAGATC GAAACCCTGAGAT-3′   This study                            N/A
  *NGN2-BRN3A* transgene RT-PCR primer, reverse: 5′-GATGGGTAC TTATGCTCAGG-3′   This study                            N/A
  *PIEZO2* exon 32 sequencing primer, forward: 5′-AGACCCAATAT GCCAACACC-3′     [@R19]                                N/A
  *PIEZO2* exon 32 sequencing primer, reverse: 5′-GGGAGCAGGCA TCATTACAA-3′     [@R19]                                N/A
  *PIEZO2* exon 35 sequencing primer, forward: 5′-GGTAAAACATC GCTGGGCTA-3′     [@R19]                                N/A
  *PIEZO2* exon 35 sequencing primer, reverse: 5′-AAGGGGTTATG CCACAACTG-3′     [@R19]                                N/A
  RT-qPCR primer - RPLP0                                                       IDT                                   Hs.PT.39a.22214824
  RT-qPCR primer - ISL1                                                        Thermo Fisher                         Hs00158126_m1
  RT-qPCR primer - POU4F1                                                      Thermo Fisher                         Hs00366711_m1
  RT-qPCR primer - NTRK1                                                       Thermo Fisher                         Hs01021011_m1
  RT-qPCR primer - NTRK2                                                       Thermo Fisher                         Hs00178811_m1
  RT-qPCR primer - PIEZO1                                                      Thermo Fisher                         Hs00207230_m1
  RT-qPCR primer - PIEZO2                                                      Thermo Fisher                         Hs00926218_m1
  RT-qPCR primer - SCN9A                                                       Thermo Fisher                         Hs00161567_m1
  RT-qPCR primer - SCN10A                                                      Thermo Fisher                         Hs01045137_m1
  RT-qPCR primer - RET                                                         Thermo Fisher                         Hs01120030_m1
  RT-qPCR primer - MAF                                                         Thermo Fisher                         Hs04185012_s1
  RT-qPCR primer - PVALB                                                       Thermo Fisher                         Hs00161045_m1
  RT-qPCR primer - TRPV1                                                       Thermo Fisher                         Hs00218912_m1
  RT-qPCR primer - TRPM8                                                       Thermo Fisher                         Hs01066596_m1
  RT-qPCR primer - SOX10                                                       Thermo Fisher                         Hs00366918_m1
  RT-qPCR primer - PAX3                                                        Thermo Fisher                         Hs00240950_m1
  RT-qPCR primer - POU5F1                                                      Thermo Fisher                         Hs00999632_g1
  RT-qPCR primer - NANOG                                                       Thermo Fisher                         Hs02387400_g1
  Recombinant DNA                                                                                                    
  pUCM-CLYBL-NGN2-BRN3A                                                        This study                            N/A
  pZT-C13-L1                                                                   [@R17]                                Addgene \#62196
  pZT-C13-R1                                                                   [@R17]                                Addgene \#62197

###### Highlights

-   *NGN2-BRN3A* expression in human stem cells induces homogeneous sensory neurons (iSNs)

-   Three kinds of iSNs can be produced, including subtypes coexpressing *TRPM8* and *PIEZO2*

-   *TRPM8* and *PIEZO2* unexpectedly mark a subset of sensory neurons in humans, but not mice

-   iSNs from PIEZO2-deficient patients are insensitive to mechanical stimuli
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